AtriCure Inc. (ATRC)

20.48
0.09 0.44
NASDAQ : Health Technology
Prev Close 20.57
Open 20.64
Day Low/High 20.41 / 20.68
52 Wk Low/High 14.88 / 25.18
Volume 9.26K
Avg Volume 217.10K
Exchange NASDAQ
Shares Outstanding 35.08M
Market Cap 743.98M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AtriCure To Present At The Needham & Company's 17th Annual Healthcare Conference

AtriCure To Present At The Needham & Company's 17th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham &...

AtriCure Reports Fourth Quarter And Full Year 2017 Financial Results

AtriCure Reports Fourth Quarter And Full Year 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2017 financial results.

AtriCure Launches The AtriClip® FLEX•V™ Device In The United States

AtriCure Launches The AtriClip® FLEX•V™ Device In The United States

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the AtriClip FLEX•V™ Left...

AtriCure Names Scott Drake Board Chairman

AtriCure Names Scott Drake Board Chairman

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Scott Drake has been named Board Chairman,...

AtriCure To Announce Fourth Quarter And Full Year 2017 Financial Results

AtriCure To Announce Fourth Quarter And Full Year 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2017...

AtriCure is Now Oversold (ATRC)

AtriCure is Now Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Reports Preliminary Results For Fourth Quarter And Full Year 2017

AtriCure Reports Preliminary Results For Fourth Quarter And Full Year 2017

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and...

AtriCure To Present At The 36th Annual JP Morgan Healthcare Conference

AtriCure To Present At The 36th Annual JP Morgan Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 36 th Annual JP Morgan...

AtriCure is Now Oversold (ATRC)

AtriCure is Now Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AtriCure To Present At The Piper Jaffray 29th Annual Healthcare Conference

AtriCure To Present At The Piper Jaffray 29th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 29 th...

AtriCure Becomes Oversold (ATRC)

AtriCure Becomes Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Reports Third Quarter 2017 Financial Results

AtriCure Reports Third Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2017 financial results.

AtriCure To Present At The Stifel Healthcare Conference

AtriCure To Present At The Stifel Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare...

AtriCure To Announce Third Quarter 2017 Financial Results

AtriCure To Announce Third Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2017 financial...

AtriCure Announces U.S. Launch Of The AtriClip® PRO•V™ Device

AtriCure Announces U.S. Launch Of The AtriClip® PRO•V™ Device

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial...

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global...

ATRC Crosses Above Average Analyst Target

ATRC Crosses Above Average Analyst Target

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $23.50, changing hands for $23.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure Reports Second Quarter 2017 Financial Results

AtriCure Reports Second Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results.

AtriCure To Present At The Canaccord Genuity 37th Annual Growth Conference

AtriCure To Present At The Canaccord Genuity 37th Annual Growth Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity...

AtriCure Announces Hiring Of Chief Technology Officer

AtriCure Announces Hiring Of Chief Technology Officer

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology...

AtriCure To Announce Second Quarter 2017 Financial Results

AtriCure To Announce Second Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2017 financial...

ATRC Crosses Above Average Analyst Target

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $22.60, changing hands for $22.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure To Present At The JMP Securities Life Science Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the JMP Securities Life...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASYS, ATRC, LMIA, MSB, MT, PCOM, SPAR, SVM, TRUE Downgrades: AEL, ASH, ASPS, IMAX, INFN, JCP Initiations: EDIT Read on to get TheStreet Quant Ratings' detailed report:

AtriCure Reports First Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2017 financial results.

AtriCure Reaches Analyst Target Price

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $20.75, changing hands for $20.89/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip ® Left...

TheStreet Quant Rating: C- (Hold)